Kern C, Schiefelbein J, Fu DJ, et al. - Researchers conducted this retrospective single-center cohort study at a tertiary referral center to evaluate visual and anatomical outcomes of intravitreal aflibercept for clinically significant diabetic macular oedema (DME). Between January 2014 and May 2018, they conducted a data warehouse query to identify 117 treatment-naive individuals (139 eyes) undergoing intravitreal treatment with aflibercept for DME. Data reported that the total number of injections per study eye was 5.5 ± 1.4 after one and 8.7 ± 2.2 injections after two years. This investigation shows that intravitreal aflibercept treating DME yields positive functional and structural outcomes over a two-year period. However, the authors observed fewer numbers of injections, along with inferior VA and structural outcomes than was reported in randomized clinical trials. The outcomes exhibit comparable results in real-life settings as for patients treated with ranibizumab due to DME.